Has Narender Gorukanti, MD received payments from drug or device companies?

Yes. Drug and device makers reported $19,679 in general payments to Narender Gorukanti, MD across 700 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Narender Gorukanti, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Narender Gorukanti, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Narender Gorukanti, MD

Hematology & Oncology · Fort Smith, ARNPI 1184659054

Payments from drug & device makers

$19,679in general payments, 2019–2025

Across 700 payments — averaging $28.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Jazz Pharmaceuticals Inc.$7K
Pfizer$1K
Novartis$1K
AstraZeneca$888
Merck$718
Amgen$525
plus $8K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Jazz Pharmaceuticals Inc.	10	$7,237
Pfizer	72	$1,144
Novartis	61	$1,011
AstraZeneca(2 entities)	49	$888
Merck	40	$718
Amgen	29	$525
Sanofi	19	$480
Genentech USA, Inc.	27	$455
Astellas Pharma US Inc	25	$410
Daiichi Sankyo Inc.	19	$393
AbbVie	20	$371
Incyte Corporation	17	$338
Regeneron Healthcare Solutions, Inc.	14	$321
Bristol Myers Squibb	18	$314
Takeda Pharmaceuticals U.S.A., Inc.	11	$267
Seagen Inc.	14	$244
Gilead(2 entities)	14	$235
Johnson & Johnson	12	$227
Lilly USA, LLC	13	$225
ADC Therapeutics America, Inc.	11	$218
Pharmacyclics LLC, An Abbvie Company	9	$215
Bayer	11	$189
E.r. Squibb & Sons, L.L.C.	12	$185
Pharmacosmos Therapeutics Inc.	10	$175
Sobi, Inc	8	$170
Eisai Inc.	10	$167
GSK	10	$153
Array Biopharma Inc	8	$147
AVEO Pharmaceuticals, Inc.	7	$144
Ipsen Biopharmaceuticals, Inc	8	$135
Boehringer Ingelheim	7	$126
Myriad Genetic Laboratories, Inc.	8	$122
Puma Biotechnology, Inc.	6	$103
Rigel Pharmaceuticals, Inc.	4	$92
Taiho Oncology, Inc.	6	$90
Myovant Sciences Inc.	4	$84
Legend Biotech USA Inc.	3	$79
G1 Therapeutics, Inc.	4	$76
Morphosys, US Inc.	4	$74
Genmab U.S., Inc.	3	$72
Kyowa Kirin, Inc.	4	$69
EMD Serono, Inc.	4	$65
Stemline Therapeutics Inc.	3	$59
Karyopharm Therapeutics Inc.	3	$56
Blueprint Medicines Corporation	3	$51
Sumitomo Pharma America, Inc.	2	$49
Mirati Therapeutics, Inc.	2	$43
Progenics Pharmaceuticals, Inc.	2	$42
CTI Biopharma Corp.	2	$34
Exelixis Inc.	2	$34
Sun Pharmaceutical Industries Inc.	2	$32
Beigene USA, Inc.	2	$31
Teva Pharmaceuticals USA, Inc.	2	$30
Beone Medicines USA, Inc.	1	$28
AMAG Pharmaceuticals, Inc.	2	$27
Verastem, Inc.	2	$27
Acrotech Biopharma Inc.	2	$26
Adaptive Biotechnologies Corporation	1	$25
Foundation Medicine, Inc.	2	$23
Tersera Therapeutics LLC	1	$21

How this compares

$19,679 in reported general payments places this provider in the 60th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas →

Medicare billing

Part B allowed, 2024

$87,065

Medicare patients

262

Services billed

913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Fort Smith

Isam Abdel-KarimFort Smith$658K
Humdum DurraniFort Smith$324K
Tony FlippinFort Smith$18K
Varant ArzoumanianFort Smith$7K
Daniel MackeyFort Smith$6K
Aswanth ReddyFort Smith$5K
John WellsFort Smith$5K
Joseph BeckFayetteville$33.8M
Eric SchaeferFayetteville$5.2M
Ryan HallLittle Rock$4.1M

See the full list for Arkansas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →